It is for these reasons that our goal is to safely disrupt the IL-1α/IL-1RA balance by the slow release of IL-1 ligands over time using appropriate delivery vehicles in combination with RT to trigger and sustain maximum systemic anti-tumor immunity. Here, IL1A is linked to neoplasm.